Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Immuneering Corporation - Class A Common Stock
(NQ:
IMRX
)
5.660
-0.120 (-2.08%)
Streaming Delayed Price
Updated: 11:11 AM EST, Dec 16, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immuneering Corporation - Class A Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 03, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Expert Ratings for Immuneering
↗
June 26, 2023
Via
Benzinga
Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors
June 05, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Present at the Jefferies Healthcare Conference
May 30, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Analyst Doubles Immuneering Price Target Citing Initial Data Validation
↗
April 19, 2023
Via
Benzinga
What 7 Analyst Ratings Have To Say About Immuneering
↗
April 19, 2023
Via
Benzinga
Why Shares of Immuneering Jumped This Week
↗
March 24, 2023
Immuneering is ready to share information regarding its lead therapy.
Via
The Motley Fool
Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates
May 04, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 19, 2023
↗
April 19, 2023
Via
Benzinga
Looking Into Immuneering's Return On Capital Employed
↗
March 09, 2023
Via
Benzinga
Immuneering Earnings Preview
↗
March 03, 2023
Via
Benzinga
Immuneering's Return On Capital Employed Insights
↗
December 20, 2022
Via
Benzinga
Immuneering Announces $30 Million Underwritten Offering
April 18, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
April 18, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 12, 2023
From
Immuneering Corporation
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
↗
April 07, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
April 06, 2023
Via
Benzinga
Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
April 05, 2023
- Investor call to be held at 9:00 a.m. ET on April 18, 2023 -
From
Immuneering Corporation
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023
↗
March 30, 2023
Via
Benzinga
Immuneering Appoints Harold E. Brakewood as Chief Business Officer
March 28, 2023
Seasoned biopharma executive with global business development, commercialization, and new product planning expertise to support the development of a universal-RAS franchise
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
March 14, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Top 5 Health Care Stocks That Are Ticking Portfolio Bombs
↗
March 14, 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
March 08, 2023
Via
Benzinga
Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
March 06, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity
March 05, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Announces Participation in March Investor Conferences
February 28, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates
February 27, 2023
Management to host conference call on Monday, March 6 at 4:30 p.m. ET
From
Immuneering Corporation
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
↗
February 03, 2023
Via
Benzinga
Immuneering To Present at Guggenheim 2023 Oncology Conference
January 31, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations
November 28, 2022
From
Immuneering Corporation
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today